261947-38-0
基本信息
化合物 CP-532623
CP 532623 >=98% (HPLC)
(2R,4S)-4-[Acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-1(2H)-quinolinecarboxylic acid 1-methylethyl ester
1(2H)-Quinolinecarboxylic acid, 4-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, 1-methylethyl ester, (2R,4S)-
物理化学性质
| 熔点 | 101.8 °C |
| 沸点 | 523.8±50.0 °C(Predicted) |
| 密度 | 1.38±0.1 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 在DMSO中的溶解度为20mg/mL，澄清 |
| 酸度系数(pKa) | -0.93±0.40(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| InChIKey | TUPKOWFPVAXQFP-OFNKIYASSA-N |
| SMILES | O=C(OC(C)C)N1C2=CC=C(C(F)(F)F)C=C2[C@@H](N(CC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C(C)=O)C[C@H]1CC |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302 |
| 防范说明 | P264-P270-P301+P312-P330-P501 |
| WGK Germany | 3 |
| 存储类别 | 11 - Combustible Solids |
| 危险性类别 | Acute Tox. 4 Oral |
CP 532623价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/12/22 | HY-123039 | CP-532623 | 261947-38-0 | 1 mg | 2550元 |
| 2025/05/22 | HY-123039 | CP 532623 CP-532623 | 261947-38-0 | 5mg | 2160元 |
| 2024/01/25 | HY-123039 | CP 532623 CP-532623 | 261947-38-0 | 10mg | 7750元 |
常见问题列表
CETP
CP-532623 is highly lymphatically transported (28% of dose), and lymphatic transport is closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions and poorly relates to solubility in mixtures of lipoprotein core and/or surface lipids. CP-532623 alters the kinetics of lymph lipid transport and decreases lymph lipid transport in chylomicrons.
CP-532623 (50 mg; oral administration; adult male greyhound dogs) treatment substantially transports into the lymphatic system (>25% dose) in fed and fasted dogs. Food enhances oral bioavailability (from 44 to 58%, respectively) and the proportion of the absorbed dose transports via the lymph (from 61 to 86% and from 68 to 83%, respectively). Lymphatic triglyceride transport is significantly lower in fed dogs administered CP-532623.
| Animal Model: | Adult male greyhound dogs (27-39 kg) |
| Dosage: | 50 mg |
| Administration: | Oral administration with a long-chain lipid formulation to fed lymphcannulated |
| Result: | Substantially transported into the lymphatic system (>25% dose) in fed and fasted dogs. Food enhanced oral bioavailability and the proportion of the absorbed dose transported via the lymph. |